Abstract:Olaf Hoffmann, 1– 3 Friedemann Paul, 3,4 Rocco Haase, 5 Raimar Kern, 6 Tjalf Ziemssen 5 1 Department of Neurology, Alexianer St. Josefs-Krankenhaus Potsdam, Potsdam, Germany; 2 Medizinische Hochschule Brandenburg Theodor Fontane, Neuruppin, Germany; 3 Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany; 4 Max Delbrueck Center for Molecular Medicine, Berlin, Germany; 5 Center of Clinical Neuroscience, Department of Neurology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany; 6 MedicalSyn GmbH, Stuttgart, Germany Correspondence: Olaf Hoffmann, Alexianer St. Josefs-Krankenhaus Potsdam, Department of Neurology, Allee nach Sanssouci 7, 14471 Potsdam, Brandenburg, Germany, Tel +49 331 9682 6000, Fax +49 331 9682 6009, Email Background: To reduce the risk of long-term disability in people with Multiple Sclerosis (pwMS), an increasing number of disease-modifying immune therapies (DMT) are available, involving diverse mechanisms of action, levels of efficacy, treatment risks, and tolerability aspects. Including patient preferences and expectations in shared decision-making may improve treatment satisfaction, adherence, and persistence. Purpose: To investigate long-term alignment of individual preferences and expectations of pwMS with their actual DMT and its effect on treatment satisfaction, health-related quality of life (HRQoL), adherence, and treatment discontinuation. Methods: A total of 401 pwMS beginning a new DMT were enrolled from 2015 to 2018 in a non-interventional study at three German MS centres. Patient preferences regarding DMT, TSQM-9, SF36, and self-reported adherence as well as relapses and EDSS were recorded at baseline and every 3 to 6 months for up to 3 years. Results: Efficacy and tolerability were the highest-ranking preferences at baseline. Actual selection of DMT corresponded more closely to safety than efficacy, tolerability, or convenience preferences. Participants reported excellent adherence throughout the study. DMT persistence was 69.0%, with earlier discontinuation for injectable vs oral or infusion therapies. Breakthrough disease, rather than patient-reported outcomes, was the main driver of DMT discontinuation. For all routes of administration, global treatment satisfaction increased over time despite lower satisfaction with convenience. Several patterns of changing preferences were observed. Conclusion: This study provides insight into the interaction of DMT preferences of pwMS with their actual treatment experience. Treatment decisions should be aligned with long-term expectations of pwMS to promote continuous adherence. Keywords: multiple sclerosis, treatment adherence and compliance, treatment discontinuation, patient preference, health-related quality of life Multiple sclerosis (MS) is the most common autoimmune demyelinating disorder of the central nervous system, affecting 2.8 million worldwide. 1 In most people with MS (pwMS), the disease is initially characterised by recurring relapses, separated by phases of complete or partial remission of symptoms (relapsing-remitting MS, RRMS), whereas about 10% experience progressive deterioration from onset (primary progressive MS, PPMS). 2 Individuals affected by RRMS, typically young adults, are at risk of accumulating neurological deficits and severe disability from clinical relapses and neurodegeneration. 3,4 Physical, cognitive, and psychiatric symptoms, as well as effects on everyday life develop in a highly individual manner. In the absence of a cure, disease-modifying therapy (DMT) aims to reduce harmful adaptive immune responses by modulating or depleting pro-inflammatory lymphocytes subsets or restricting their access to the CNS. 5 Effective control of inflammatory disease activity, ie, preventing relapses and formation of new lesions on MRI, slows the accumulation of disability and reduces the risk of transitioning from RRMS to a secondary chronic progressive course (SPMS) that is much less amenable to DMT. 6 Over the past decade, immunomodulatory therapy options for pwMS have expanded significantly, involving different routes of application (oral, infusion, subcutaneous or intramuscular injection) and frequencies of treatment. 5 Diverse mechanisms of action translate into moderately vs highly efficient therapies (MET, HET) as well as drug-specific safety and tolerability aspects. 5,7 In parallel, individual prognostication has improved, considering personal co-factors as well as MRI findings and liquid b -Abstract Truncated-

Adherence and Persistence to Drug Therapies for Multiple Sclerosis: A Population-Based Study

Medication Adherence in Multiple Sclerosis As a Potential Model for Other Chronic Diseases: a Population-Based Cohort Study.

Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis

Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study.

Adherence to Laboratory Monitoring among People Taking Oral Drugs for Multiple Sclerosis: A Canadian Population-Based Study

Real‐world persistence of multiple sclerosis disease‐modifying therapies

Personalized Intervention to Improve Medication Adherence for Persons with Multiple Sclerosis

Adherence to disease-modifying therapies and attitudes regarding disease in patients with multiple sclerosis

Preferences, Adherence, and Satisfaction: Three Years of Treatment Experiences of People with Multiple Sclerosis

Association of Oral Disease-modifying Agents and Their Adherence Trajectories with Annual Relapses in Multiple Sclerosis

Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study

Barriers and strategies to medication adherence amongst people with multiple sclerosis and cognitive problems

[Adherence to treatment in the management of patients with multiple sclerosis]

Adherence to disease-modifying therapy in multiple sclerosis: Part I

The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosis

Disease-modifying Drugs, Multiple Sclerosis and Infection-Related Healthcare Use in British Columbia, Canada: a Population-Based Study.

Disparities in DMT treatment: Demographic and neurocognitive differences between MS patients currently treated versus not treated with disease-modifying therapies

Switching to second line MS disease-modifying therapies is associated with decreased relapse rate

Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

Disease-modifying therapy initiation patterns in multiple sclerosis in three large MS populations

Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population